March 2008

TABLE OF CONTENTS

The Management Buy-Out: What’s a Fair Price?
Derrek G. Hennecke, MBA, continues with part 2 of his 7-part series chronicling the challenges, issues, and more importantly, the opportunities he faced throughout his Management Buy-Out. 

Addressing the Analgesic Gap in Breakthrough Cancer Pain ““ A Drug Delivery Case Study

Josef Bossart, PhD, and Taneli Jouhikainen, MD, PhD, review some of the thinking and strategies being implemented to fill or bridge the Analgesic Gap through the rational application of drug delivery technology.

 

Annual Update on Non-Invasive Insulin Delivery Technologies

Avani Amin, MPharm, PhD; Tejal Shah, MPharm; Jagruti Patel, MPharm, PhD; and Anuradha Gajjar, MPharm, PhD; presents an update on the progress of the non-invasive delivery technologies for insulin since last year’s update featured in the March 2007 issue of this publication.

 

Oral Drug Delivery: Hurdles in Oral Product Development & the Need for Continued Technology Investment

Daniel Ruppar believes as biopharmaceutical and specialty pharma products expand the importance for revenue streams for companies in the future, continued investment in oral technologies to deliver these products to patients is expected to become increasingly important.

 

Life Cycle Management: Taking an Aggressive Approach

Douglas Martin, MD, suggests taking an aggressive “strategic innovation” approach to leverage years of research to identify molecular entities similar to an expiring blockbuster and erecting new exclusivity barriers for these follow-on drugs by targeting strategically chosen indications.

 

Measuring the Solubility of a Model Drug in Drug-in-Adhesive Transdermal Patches to Validate a Theoretical Solubility Calculator

Rachael Myatt, Gbolahan Oladiran, and Hannah Batchelor, PhD, provide research to validate the use of a theoretical solubility calculator by comparing the solubility of sodium fluorescein, a model hydrophilic drug, in a range of DURO-TAK adhesives using Higuchi kinetics to measure the experimental solubility.

 

SCOLR Pharma, Inc.: A Differentiated Oral Drug Delivery Company

Drug Delivery Executive: Daniel O. Wilds, President and CEO of SCOLR, discusses how his company intends to commercialize products independently and through third-party alliances with pharmaceutical and other industry partners utilizing its unique CDT delivery platform.

 

Analytical Laboratories: Trends, Management & Relationships

Contributor Cindy H. Dubin recently asked several of the industry’s leading analytical laboratories about trends in the sector, project management, and how Specialty Pharma companies can best manage relationships with providers.

 

NasVax: Improving Vaccines With a Unique Platform

Executive Summary: Dr. Ronald Ellis, Senior VP & CTO for NasVax, discusses how the company built up its management team, completed two private investment rounds, and had a successful IPO to become a publicly traded company on the Tel Aviv Stock Exchange.

 

The Challenges of Medical Diversity

Udo Kiessling, MD, PhD, questions whether different therapeutic areas and various diseases require a specific approach in drug development, highlighting key differences among three major therapeutic areas with regard to success rates in clinical development. Ellis

Senior Vice President, Chief Technology Off

DEPARTMENTS

 

Market News & Trends

 

Business Development

What is the Value of Your Company?

 

Combination Update

Understanding the Regulatory Environment for Combination Products in the World’s Leading Markets

 

Excipient Update

Big Pharma & Suppliers Collaborate on Excipient Quality

 

Technology Showcase

 

Facts & Figures

 

External Delivery

SARs Analysis                        

COVER

FEATURES